Czech Republic

BMI View: The Czech pharmaceutical market is the most developed in terms of spending and ease of operating the Central and Eastern European region, but it continues to present challenges... 2013-02-22

BMI View: In our Q113 assessment, we have revised downward our Pharmaceuticals and Healthcare Risk/Reward Ratings (RRRs) for Central and Eastern Europe (CEE), mainly due to the attractiveness... 2012-10-03

BMI View: Proposed legislative amendments to healthcare and pharmaceutical policy are negative for pharmaceutical companies operating in the Czech Republic, though not as damaging as... 2012-09-11

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2012-03-12

BMI View: It is clear that the Czech Republic pharmaceutical and healthcare market will be under intense pressure in 2012, the combination of drug policy reforms and a weak economic... 2012-02-02

BMI View: A worsening economic outlook, combined with comments from the Czech health minister Leos Heger in mid-November 2011, indicate that public funding for healthcare services will... 2011-11-17